{"id":42295,"date":"2018-06-06T11:24:49","date_gmt":"2018-06-06T10:24:49","guid":{"rendered":"https:\/\/blogs.bmj.com\/bmj\/?p=42295"},"modified":"2018-06-12T14:51:16","modified_gmt":"2018-06-12T13:51:16","slug":"magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/","title":{"rendered":"Magdalena Zwierzyna: Lessons on trial design and transparency from ClinicalTrials.gov"},"content":{"rendered":"<p><span style=\"font-weight: 400\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-42297\" src=\"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/06\/Magdalena_Zwierzyna_2018.png\" alt=\"\" width=\"168\" height=\"147\" \/>Over time, ClinicalTrials.gov has accumulated a powerful dataset that offers a remarkable opportunity to study trends in the current clinical research landscape. The world&#8217;s largest primary clinical trials registry enables researchers and physicians to identify studies in their specialty and collect clinical evidence. It allows patients to search for trials that are actively recruiting participants. It is even used by the <\/span><a style=\"font-size: 1rem;background-color: #ffffff\" href=\"https:\/\/trialstracker.ebmdatalab.net\/#\/\">FDAAA trials tracker<\/a><span style=\"font-weight: 400\"> to <\/span><a style=\"font-size: 1rem;background-color: #ffffff\" href=\"https:\/\/blogs.bmj.com\/bmj\/category\/unreported-trial-of-the-week\/\">identify and challenge<\/a><span style=\"font-weight: 400\"> trial sponsors who do not comply with <\/span><a style=\"font-size: 1rem;background-color: #ffffff\" href=\"https:\/\/www.gpo.gov\/fdsys\/pkg\/PLAW-110publ85\/pdf\/PLAW-110publ85.pdf#page=82\">transparency legislation<\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><span style=\"font-weight: 400\">The increasingly data driven approaches to research and development in the drug discovery industry also benefit from the resource. At BenevolentAI, <\/span><span style=\"font-weight: 400\">a British drug discovery company<\/span><span style=\"font-weight: 400\">, we used ClinicalTrials.gov to ensure that <\/span><a href=\"http:\/\/benevolent.ai\/blog\/benevolentai\/whats-in-a-name-our-first-clinical-trial\/\"><span style=\"font-weight: 400\">the name of our first trial<\/span><\/a><span style=\"font-weight: 400\"> was not similar to the acronym of any ongoing or past study. More importantly, the data help\u00a0our<\/span><i><span style=\"font-weight: 400\">\u00a0<\/span><\/i><span style=\"font-weight: 400\">drug discovery researchers identify unmet needs, interesting assets, and potential collaborators. Available summary protocol data for hundreds of past studies are also extremely useful when planning study design. How big are trials in a given disease? How long do they typically take? How many centres are involved in recruitment? What are commonly used outcome measures, eligibility criteria, and comparators? Modern text mining and data analytics approaches help us answer such questions, and learn from past clinical trials to improve the design of studies in the future.<\/span><\/p>\n<p><span style=\"font-weight: 400\">It was when attempting to tackle some of these typical study design questions that we became interested in the apparent heterogeneity of registered trials.\u2028 Even after accounting for obvious outliers (such as interventional trials with reported recruitment <\/span><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02361008\"><span style=\"font-weight: 400\">exceeding 1 000 000 participants<\/span><\/a><span style=\"font-weight: 400\">),\u00a0it turns out that even within the same disease category and study phase, the differences in sample size or trial duration can be huge.\u2028 In other words, the so-called typical trial simply does not exist.\u2028<\/span><\/p>\n<p><span style=\"font-weight: 400\">We took up the challenge to further investigate the differences between trials systematically and analysed a dataset covering all completed interventional studies registered with ClinicalTrials.gov since 2005. We also linked the registry records to a database of published scientific literature to investigate associations between trial design and publication in medical journals, helping to address one of the most important questions in medical research: the transparency and reporting of clinical studies.<\/span><\/p>\n<p><span style=\"font-weight: 400\"><a href=\"https:\/\/www.bmj.com\/content\/361\/bmj.k2130\">Our research paper<\/a> (<\/span><i><span style=\"font-weight: 400\">BMJ<\/span><\/i><span style=\"font-weight: 400\"> 2018;361:k2130<\/span><span style=\"font-weight: 400\">)<\/span> <span style=\"font-weight: 400\">found that trial phase, size, design, and even medical specialty are all associated with the likelihood of trial publication in medical journals. For instance, oncology had the lowest rate of results publication across all disease areas, with only a fifth of all cancer studies published in a journal. Is this low rate because of the high prevalence of small sample sizes and non-randomised designs in this field? Or perhaps because of the fact that so many cancer trials fail to show positive outcomes?\u2028 One thing is for certain: the evidence available in scientific literature is largely incomplete, and could be distorted as well.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Here\u2019s one encouraging finding: the results database of ClinicalTrials.gov seems much less biased than the medical literature. Not only does it store the results of many small non-randomised studies that are not published elsewhere, but the time to results dissemination is also faster and the differences across medical specialties are much less pronounced. Not all organisations, however, are equally likely to submit their results to the portal. Trial reporting rates are highest for big pharma and the National Institutes of Health, followed by smaller industrial organisations, but universities and other non-profit funders still lag behind. As more academic institutions enter the clinical trial arena, it is important to better understand how this sector compares to industry, and our analysis identified several differences in both trial design and results dissemination. Whether we explain these trends by differences in regulations, objectives, available resources, or awareness of the FDAAA legislation, the situation needs to be addressed.<\/span><\/p>\n<p><span style=\"font-weight: 400\">The struggle for transparency must continue. With over 270 000 registered studies and almost 30 000 result summaries, ClinicalTrials.gov already has an important role in collecting evidence from clinical research. Still, we are a long way from where we need to be. To put things into scale, the entire content of the clinical trial registry can be downloaded in a single file, just over 1 gigabyte in size. There are a lot more clinical data out there that should be made available. We hope that the findings from our study and from others will help improve our understanding of the complexities of trial dissemination, and\u2014ultimately\u2014lead to better access to data from all clinical trials.<\/span><\/p>\n<p><em><span style=\"font-weight: 400\"><strong>Magdalena Zwierzyna<\/strong> is a biomedical data scientist at BenevolentAI, a British artificial intelligence drug discovery company. She is also pursuing a PhD in bioinformatics at University College London. You can follow her on\u00a0<\/span><span style=\"font-weight: 400\">Twitter <a href=\"https:\/\/twitter.com\/magda_zw\">@magda_zw<\/a><\/span><\/em><\/p>\n<p><strong>Competing interests:<\/strong> None declared.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Over time, ClinicalTrials.gov has accumulated a powerful dataset that offers a remarkable opportunity to study trends in the current clinical research landscape. The world&#8217;s largest primary clinical trials registry enables [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/\">More&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":42302,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18894],"tags":[],"class_list":["post-42295","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-authors-perspective"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Magdalena Zwierzyna: Lessons on trial design and transparency from ClinicalTrials.gov - The BMJ<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Magdalena Zwierzyna: Lessons on trial design and transparency from ClinicalTrials.gov - The BMJ\" \/>\n<meta property=\"og:description\" content=\"Over time, ClinicalTrials.gov has accumulated a powerful dataset that offers a remarkable opportunity to study trends in the current clinical research landscape. The world&#8217;s largest primary clinical trials registry enables [...]More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/\" \/>\n<meta property=\"og:site_name\" content=\"The BMJ\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/bmjdotcom\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-06-06T10:24:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-06-12T13:51:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/06\/clinicaltrials_website-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"540\" \/>\n\t<meta property=\"og:image:height\" content=\"350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BMJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:site\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BMJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/06\\\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/06\\\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\\\/\"},\"author\":{\"name\":\"BMJ\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\"},\"headline\":\"Magdalena Zwierzyna: Lessons on trial design and transparency from ClinicalTrials.gov\",\"datePublished\":\"2018-06-06T10:24:49+00:00\",\"dateModified\":\"2018-06-12T13:51:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/06\\\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\\\/\"},\"wordCount\":792,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/06\\\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/06\\\/clinicaltrials_website-2.jpg\",\"articleSection\":[\"Author's perspective\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/06\\\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/06\\\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/06\\\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\\\/\",\"name\":\"Magdalena Zwierzyna: Lessons on trial design and transparency from ClinicalTrials.gov - The BMJ\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/06\\\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/06\\\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/06\\\/clinicaltrials_website-2.jpg\",\"datePublished\":\"2018-06-06T10:24:49+00:00\",\"dateModified\":\"2018-06-12T13:51:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/06\\\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/06\\\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/06\\\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/06\\\/clinicaltrials_website-2.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/06\\\/clinicaltrials_website-2.jpg\",\"width\":540,\"height\":350},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/06\\\/06\\\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Magdalena Zwierzyna: Lessons on trial design and transparency from ClinicalTrials.gov\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"name\":\"The BMJ\",\"description\":\"Helping doctors make better decisions.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\",\"name\":\"The BMJ\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"width\":852,\"height\":568,\"caption\":\"The BMJ\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/bmjdotcom\\\/\",\"https:\\\/\\\/x.com\\\/bmj_latest\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\",\"name\":\"BMJ\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"caption\":\"BMJ\"},\"sameAs\":[\"https:\\\/\\\/blogs.bmj.com\\\/\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Magdalena Zwierzyna: Lessons on trial design and transparency from ClinicalTrials.gov - The BMJ","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/","og_locale":"en_US","og_type":"article","og_title":"Magdalena Zwierzyna: Lessons on trial design and transparency from ClinicalTrials.gov - The BMJ","og_description":"Over time, ClinicalTrials.gov has accumulated a powerful dataset that offers a remarkable opportunity to study trends in the current clinical research landscape. The world&#8217;s largest primary clinical trials registry enables [...]More...","og_url":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/","og_site_name":"The BMJ","article_publisher":"https:\/\/www.facebook.com\/bmjdotcom\/","article_published_time":"2018-06-06T10:24:49+00:00","article_modified_time":"2018-06-12T13:51:16+00:00","og_image":[{"width":540,"height":350,"url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/06\/clinicaltrials_website-2.jpg","type":"image\/jpeg"}],"author":"BMJ","twitter_card":"summary_large_image","twitter_creator":"@bmj_latest","twitter_site":"@bmj_latest","twitter_misc":{"Written by":"BMJ","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/"},"author":{"name":"BMJ","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe"},"headline":"Magdalena Zwierzyna: Lessons on trial design and transparency from ClinicalTrials.gov","datePublished":"2018-06-06T10:24:49+00:00","dateModified":"2018-06-12T13:51:16+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/"},"wordCount":792,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/06\/clinicaltrials_website-2.jpg","articleSection":["Author's perspective"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/","url":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/","name":"Magdalena Zwierzyna: Lessons on trial design and transparency from ClinicalTrials.gov - The BMJ","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/06\/clinicaltrials_website-2.jpg","datePublished":"2018-06-06T10:24:49+00:00","dateModified":"2018-06-12T13:51:16+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/#primaryimage","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/06\/clinicaltrials_website-2.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/06\/clinicaltrials_website-2.jpg","width":540,"height":350},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/06\/06\/magdalena-zwierzyna-lessons-on-trial-design-and-transparency-from-clinicaltrials-gov\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/bmj\/"},{"@type":"ListItem","position":2,"name":"Magdalena Zwierzyna: Lessons on trial design and transparency from ClinicalTrials.gov"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/bmj\/#website","url":"https:\/\/blogs.bmj.com\/bmj\/","name":"The BMJ","description":"Helping doctors make better decisions.","publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/bmj\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/bmj\/#organization","name":"The BMJ","url":"https:\/\/blogs.bmj.com\/bmj\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","width":852,"height":568,"caption":"The BMJ"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/bmjdotcom\/","https:\/\/x.com\/bmj_latest"]},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe","name":"BMJ","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","caption":"BMJ"},"sameAs":["https:\/\/blogs.bmj.com\/"],"url":"https:\/\/blogs.bmj.com\/bmj\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/42295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/comments?post=42295"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/42295\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/media\/42302"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/media?parent=42295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/categories?post=42295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/tags?post=42295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}